PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
2156661-2	1990	The purpose of this study was to examine the effect of intravenous administration of terbutaline on plasma levels of peptide YY (PYY) and gastric inhibitory polypeptide (GIP), both of which are known to inhibit gastric acid secretion.	Terbutaline	85-96	peptide YY	Canis lupus familiaris	129-132	
2156661-0	1990	Terbutaline, a beta 2-adrenoreceptor agonist, inhibits gastric acid secretion and stimulates release of peptide YY and gastric inhibitory polypeptide in dogs.	Terbutaline	0-11	peptide YY	Canis lupus familiaris	104-114	
2156661-2	1990	The purpose of this study was to examine the effect of intravenous administration of terbutaline on plasma levels of peptide YY (PYY) and gastric inhibitory polypeptide (GIP), both of which are known to inhibit gastric acid secretion.	Terbutaline	85-96	peptide YY	Canis lupus familiaris	117-127	
2156661-5	1990	Terbutaline significantly increased plasma PYY levels, 24% in response to terbutaline at 10 micrograms/kg/hr, and 59% at 20 micrograms/kg/hr.	Terbutaline	0-11	peptide YY	Canis lupus familiaris	43-46	
2156661-7	1990	Our data suggest that terbutaline-induced inhibition of pentagastrin-stimulated gastric acid secretion is mediated, at least in part, by the release of PYY and GIP.	Terbutaline	22-33	peptide YY	Canis lupus familiaris	152-155